Partner Headlines - BMRN

  1. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  2. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  3. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  4. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  5. BioMarin buying Prosensa

    IBD
  6. Trio Of Major Deals Disclosed

    IBD
  7. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  8. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  9. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  10. Benzinga's Volume Movers

    Benzinga
  11. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  12. Stocks Hitting 52-Week Highs

    Benzinga
  13. Morning Market Movers

    Benzinga
  14. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  15. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  16. Benzinga's Top #PreMarket Gainers

    Benzinga
  17. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  18. Stocks Hitting 52-Week Highs

    Benzinga
  19. Benzinga's Top Upgrades

    Benzinga
  20. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  21. BioMarin Weathers The Storm

    Benzinga
  22. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  23. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  24. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  25. Benzinga's Top Upgrades

    Benzinga
  26. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  27. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  28. Top Trending Tickers On StockTwits For February 18

    Benzinga
  29. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  30. You Can No Longer Ignore Biotech

    GuruFocus
  31. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  32. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  33. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  34. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  35. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  36. Benzinga's Top #PreMarket Gainers

    Benzinga
  37. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  38. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  39. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  40. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  41. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  42. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  43. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  44. Roche

    IBD
  45. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  46. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  47. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  48. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  49. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  50. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  51. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  52. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  53. Benzinga's Volume Movers

    Benzinga
  54. Benzinga's Top Pre-Market Gainers

    Benzinga
  55. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  56. Benzinga's Top Pre-Market Gainers

    Benzinga
  57. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  58. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  59. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  60. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  61. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  62. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  63. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  64. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  65. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  66. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  67. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  68. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  69. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  70. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  71. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  72. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  73. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  74. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  75. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  76. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  77. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  78. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  79. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  80. BioMarin soars on drug data

    IBD
  81. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  82. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  83. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
  84. Stocks Hitting 52-Week Highs

    Benzinga
  85. BioMarin Stock Soars On Positive Drug Data

    IBD
  86. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga
  87. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  88. BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q)

    GuruFocus
  89. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  90. UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical ...

    Benzinga
  91. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  92. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  93. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  94. Health Care Sector Wrap

    FoxBusiness
  95. Benzinga's Top Downgrades

    Benzinga
  96. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  97. BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ ...

    Benzinga
  98. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  99. BioMarin Pharmaceutical, Health Net Among Stocks Up on High Volume ...

    FoxBusiness
  100. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
Trading Center